Mihael H. Polymeropoulos, M.D., is a distinguished figure in the pharmaceutical industry, currently serving as the President and Chief Executive Officer at Vanda Pharmaceuticals Inc. Dr. Polymeropoulos has been at the helm of Vanda since its inception in 2004, guiding the company through its evolution into a fully integrated biopharmaceutical entity. His leadership has been instrumental in the development and commercialization of innovative therapies, particularly in the fields of central nervous system disorders and other unmet medical needs. Before joining Vanda, Dr. Polymeropoulos amassed extensive experience in the pharmaceutical sector. He spent over a decade at the National Institutes of Health (NIH), where he was involved in groundbreaking genetic research that contributed to the identification of several disease-related genes. Following his tenure at the NIH, he transitioned to the private sector, holding key positions at Novartis Pharmaceuticals Corporation. At Novartis, he played a pivotal role in the development and launch of several successful drugs, further honing his skills in drug discovery and development. Under Dr. Polymeropoulos's leadership, Vanda Pharmaceuticals has achieved significant milestones, including the successful launch of HETLIOZ® for Non-24-Hour Sleep-Wake Disorder and Fanapt® for schizophrenia. His strategic vision has not only driven the company's growth but also ensured its commitment to addressing critical healthcare challenges. Dr. Polymeropoulos's dedication to advancing medical science and improving patient outcomes continues to shape Vanda's mission and operations, solidifying its position as a leader in the biopharmaceutical industry.